BRIEF—EC approval for shorter Maviret treatment duration

The European Commission has approved a change to the marketing authorization for Maviret (glecaprevir/pibrentasvir) to shorten once-daily treatment duration from 12 to eight weeks in treatment-naïve, compensated cirrhotic, chronic hepatitis C virus (HCV).

This makes the AbbVie drug the only eight-week treatment regimen indicated for all common HCV genotypes in treatment-naïve, chronic HCV patients both without cirrhosis or with compensated cirrhosis, without the need for HCV genotype testing.

Maviret was already indicated as an eight-week, pan-genotypic, once-daily regimen for treatment-naïve HCV patients without cirrhosis, and as an eight-week, once-daily regimen for treatment-naïve GT 1, 2, 4, 5 and 6 HCV patients with compensated cirrhosis.